Endocrine Resistant Breast Cancer: Brain Metastasis

Overview

Journal Explor Target Antitumor Ther

Specialty Oncology

Date 2022 May 4

PMID 35505937

Authors

Matthew Willman

Jonathan Willman

Brandon Lucke-Wold

Affiliations

Soon will be listed here.

Abstract

Endocrine resistant breast cancer metastasis continues to serve as a significant clinical challenge with high morbidity and mortality for patients. As the number of breast cancer cases continues to rise, the rate of brain metastasis has also increased. For single lesions or a large symptomatic lesion with other smaller lesions, surgical resection is a viable option in non-eloquent regions. Stereotactic radiosurgery is a great option for post-operative therapy or for 10 or fewer small lesions (< 3 cm in size). Whole-brain radiation can be used sparingly for large tumor burdens but should encompass hippocampus sparing techniques. Chemotherapy options have remained relatively limited due to decreased permeability of the blood-brain barrier. Emerging monoclonal antibody treatments have offered initial promise, especially for endocrine resistant breast cancer metastasis.

Citing Articles

Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer.

Gu Y, Yang R, Zhang Y, Guo M, Takehiro K, Zhan M Mol Biomed. 2025; 6(1):2.

PMID: 39757310 PMC: 11700966. DOI: 10.1186/s43556-024-00239-2.

Retrospective Analysis of Pyrotinib-Based Therapy for Metastatic Breast Cancer: Promising Efficacy in Combination with Trastuzumab.

Gu Q, Zhu M, Wang Y, Gu Y Breast Cancer (Dove Med Press). 2024; 16:253-268.

PMID: 38812479 PMC: 11135571. DOI: 10.2147/BCTT.S457845.

Long non-coding RNA SOX2OT in tamoxifen-resistant breast cancer.

Lee J, Kim E, Kang J, Chae Y, Park H, Kang B BMC Mol Cell Biol. 2024; 25(1):12.

PMID: 38649821 PMC: 11036730. DOI: 10.1186/s12860-024-00510-y.

Clinical and pathological factors and outcome of central nervous system metastasis in breast cancer.

Dettwiler D, Chiru E, Daetwyler E, Dougoud-Chauvin V, Gross M, Kurzeder C Front Oncol. 2023; 13:1247402.

PMID: 37795444 PMC: 10546422. DOI: 10.3389/fonc.2023.1247402.

Research trends and prospects on brain metastasis from breast cancer: A bibliometric analysis.

Wu S, Liu Y, Zhou J, You Y, Zhou X, Chen L Front Oncol. 2023; 13:1091249.

PMID: 37091185 PMC: 10113486. DOI: 10.3389/fonc.2023.1091249.

References

Singh Achrol A, Rennert R, Anders C, Soffietti R, Ahluwalia M, Nayak L . Brain metastases. Nat Rev Dis Primers. 2019; 5(1):5. DOI: 10.1038/s41572-018-0055-y. View

Lei J, Anurag M, Haricharan S, Gou X, Ellis M . Endocrine therapy resistance: new insights. Breast. 2019; 48 Suppl 1:S26-S30. PMC: 6939855. DOI: 10.1016/S0960-9776(19)31118-X. View

Bailleux C, Eberst L, Bachelot T . Treatment strategies for breast cancer brain metastases. Br J Cancer. 2020; 124(1):142-155. PMC: 7782834. DOI: 10.1038/s41416-020-01175-y. View

Laoukili J, Kooistra M, Bras A, Kauw J, Kerkhoven R, Morrison A . FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol. 2005; 7(2):126-36. DOI: 10.1038/ncb1217. View

Spoerke J, Gendreau S, Walter K, Qiu J, Wilson T, Savage H . Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nat Commun. 2016; 7:11579. PMC: 4869259. DOI: 10.1038/ncomms11579. View

Wang Y, Tzeng Y, Chang G, Wang X, Chen S . Amphiregulin retains ERα expression in acquired aromatase inhibitor resistant breast cancer cells. Endocr Relat Cancer. 2020; 27(12):671-683. PMC: 7665895. DOI: 10.1530/ERC-20-0258. View

Wu Q, Liu C, Tai M, Liu D, Lei L, Wang R . Knockdown of FoxM1 by siRNA interference decreases cell proliferation, induces cell cycle arrest and inhibits cell invasion in MHCC-97H cells in vitro. Acta Pharmacol Sin. 2010; 31(3):361-6. PMC: 4002417. DOI: 10.1038/aps.2010.4. View

Millour J, Constantinidou D, Stavropoulou A, Wilson M, Myatt S, Kwok J . FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance. Oncogene. 2010; 29(20):2983-95. PMC: 2874720. DOI: 10.1038/onc.2010.47. View

Shah M, Wedam S, Cheng J, Fiero M, Xia H, Li F . FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast Cancer. Clin Cancer Res. 2020; 27(5):1220-1226. DOI: 10.1158/1078-0432.CCR-20-2701. View

10.

Cacho-Diaz B, Spinola-Marono H, Arrieta V, Granados-Garcia M, Wegman-Ostrosky T, Mendoza-Olivas L . Diagnosis of brain metastases in breast cancer patients resulting from neurological symptoms. Clin Neurol Neurosurg. 2018; 173:61-64. DOI: 10.1016/j.clineuro.2018.08.002. View

11.

Watase C, Shiino S, Shimoi T, Noguchi E, Kaneda T, Yamamoto Y . Breast Cancer Brain Metastasis-Overview of Disease State, Treatment Options and Future Perspectives. Cancers (Basel). 2021; 13(5). PMC: 7959316. DOI: 10.3390/cancers13051078. View

12.

Brett J, Spring L, Bardia A, Wander S . ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Res. 2021; 23(1):85. PMC: 8365900. DOI: 10.1186/s13058-021-01462-3. View

13.

Kwon Y, Nam K, Kim S . Tamoxifen overcomes the trastuzumab-resistance of SK-BR-3 tumorspheres by targeting crosstalk between cytoplasmic estrogen receptor α and the EGFR/HER2 signaling pathway. Biochem Pharmacol. 2021; 190:114635. DOI: 10.1016/j.bcp.2021.114635. View

14.

Kienast Y, von Baumgarten L, Fuhrmann M, Klinkert W, Goldbrunner R, Herms J . Real-time imaging reveals the single steps of brain metastasis formation. Nat Med. 2009; 16(1):116-22. DOI: 10.1038/nm.2072. View

15.

Krishnan M, Krishnamurthy J, Shonka N . Targeting the Sanctuary Site: Options when Breast Cancer Metastasizes to the Brain. Oncology (Williston Park). 2019; 33(8). View

16.

Zhang Y, Ma Y, Zeng Y, Liu Y, He E, Liu Y . A narrative review of research progress on FoxM1 in breast cancer carcinogenesis and therapeutics. Ann Transl Med. 2022; 9(22):1704. PMC: 8667115. DOI: 10.21037/atm-21-5271. View

17.

Akanda Z, Hong W, Nahavandi S, Haghighi N, Phillips C, Kok D . Post-operative stereotactic radiosurgery following excision of brain metastases: A systematic review and meta-analysis. Radiother Oncol. 2019; 142:27-35. DOI: 10.1016/j.radonc.2019.08.024. View

18.

Ren D, Cheng H, Wang X, Vishnoi M, Teh B, Rostomily R . Emerging treatment strategies for breast cancer brain metastasis: from translational therapeutics to real-world experience. Ther Adv Med Oncol. 2020; 12:1758835920936151. PMC: 7328353. DOI: 10.1177/1758835920936151. View

19.

Ni W, Chen W, Lu Y . Emerging findings into molecular mechanism of brain metastasis. Cancer Med. 2018; 7(8):3820-3833. PMC: 6089171. DOI: 10.1002/cam4.1667. View

20.

Hartkopf A, Grischke E, Brucker S . Endocrine-Resistant Breast Cancer: Mechanisms and Treatment. Breast Care (Basel). 2020; 15(4):347-354. PMC: 7490658. DOI: 10.1159/000508675. View